Search results for "Muscular Atrophy"

showing 10 items of 73 documents

Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey.

2022

ObjectiveSpinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in the SMN1 gene. The aim of this study was to assess the prevalence of SMA and treatment prescription in Italy.MethodsAn online survey was distributed to 36 centers identified by the Italian government as referral centers for SMA. Data on the number of patients with SMA subdivided according to age, type,SMN2copy number, and treatment were collected.ResultsOne thousand two hundred fifty-five patients with SMA are currently followed in the Italian centers with an estimated prevalence of 2.12/100,000. Of the 1,255, 284 were type I, 470 type II, 467 type III, and 15 type IV with estimated prevalence of 0…

Settore MED/39 - NEUROPSICHIATRIA INFANTILESettore MED/48 - SCIENZE INFERMIERISTICHE E TECNICHE NEURO-PSICHIATRICHE E RIABILITATIVEspinal muscular atrophy; smaepidemiologySettore MED/26 - NeurologiaNeurology (clinical)Spinal muscular atrophy (SMA) disease modifying therapies SMN1 SMN2 prevalenceITALIAN REGISTRYsmaSettore MED/42 - IGIENE GENERALE E APPLICATAPREVALENCEspinal muscular atrophyNeurology
researchProduct

Phenotypic spectrum and incidence of TRPV4 mutations in patients with inherited axonal neuropathy.

2014

Objective: To clarify the phenotypic spectrum and incidence of TRPV4 mutations in patients with inherited axonal neuropathies. Methods: We screened for TRPV4 mutations in 169 French unrelated patients with inherited axonal peripheral neuropathy. Ninety-five patients had dominant Charcot-Marie-Tooth type 2 (CMT2) disease, and 74 patients, including 39 patients with distal hereditary motor neuropathy, 14 with congenital spinal muscular atrophy and arthrogryposis, 13 with CMT2, and 8 with scapuloperoneal spinal muscular atrophy, presented with additional vocal cord paralysis and/or skeletal dysplasia. Results: No deleterious TRPV4 mutation was identified in the 95 patients with “pure” CMT2 (0/…

TRPV4AdultMalePathologymedicine.medical_specialtyAdolescentTRPV Cation ChannelsYoung AdultMedicineMissense mutationHumansVocal cord paralysisHereditary Sensory and Autonomic NeuropathiesChildKyphoscoliosisAgedArthrogryposisbusiness.industryMusclesSpinal muscular atrophyMiddle Agedmedicine.diseasePhenotypeDysplasiaMutationFemaleNeurology (clinical)Francemedicine.symptomBone DiseasesbusinessAsymptomatic carrierNeurology
researchProduct

A Spinal Muscular Atrophy Reporter System for in vivo Drug Discovery in Drosophila melanogaster

2018

Fondo La Atrofia Muscular Espinal es un desorden neuromuscular raro y fatal causado por la pérdida o reducción en los niveles de proteína de la Neurona Motor de Supervivencia (SMN). Los individuos afectados tienen el gen SMN1 mutado y la copia SMN2 específica de humanos no afectada, que se traduce solo parcialmente en una proteína SMN funcional. La activación farmacológica de la inclusión del exón 7 de SMN2 por moléculas pequeñas o oligonucleótidos antisentido modificados es un enfoque prometedor para tratar la SMA. Obtener nuevos compuestos potencialmente terapéuticos para los ensayos clínicos es un proceso largo y costoso. El enfoque de reposicionamiento de medicamentos puede reducir el t…

UNESCO::CIENCIAS DE LA VIDAdrosophila melanogasternervous system diseasesdrug discoveryspinal muscular atrophy
researchProduct

Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts’ study

2021

ABSTRACTObjectiveTo assess safety and efficacy of nusinersen in adult 5q spinal muscular atrophy (SMA) patients.MethodsPatients older than 15 years and followed at least for 6 months with one motor scale (Hammersmith Functional Motor Scale Expanded, HFMSE; Revised Upper Limb module, RULM) in five referral centers were included. Clinical and patients’ global impression of change (CGI-C and PGI-C) were recorded in treated patients at the last visit. Functional scales (Egen Klassification, EK2; Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, ALSFRS-R) and the percent-predicted forced vital capacity were collected when available.ResultsSeventy-nine SMA patients (39 treated with n…

Vital capacitymedicine.medical_specialtybusiness.industrySpinal muscular atrophySMA*medicine.diseasemedicine.anatomical_structureRating scaleInternal medicinemedicineUpper limbNusinersenAmyotrophic lateral sclerosisbusinessAdverse effect
researchProduct

Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model

2015

ABSTRACT Muscle mass wasting is one of the most debilitating symptoms of myotonic dystrophy type 1 (DM1) disease, ultimately leading to immobility, respiratory defects, dysarthria, dysphagia and death in advanced stages of the disease. In order to study the molecular mechanisms leading to the degenerative loss of adult muscle tissue in DM1, we generated an inducible Drosophila model of expanded CTG trinucleotide repeat toxicity that resembles an adult-onset form of the disease. Heat-shock induced expression of 480 CUG repeats in adult flies resulted in a reduction in the area of the indirect flight muscles. In these model flies, reduction of muscle area was concomitant with increased apopto…

lcsh:MedicineMedicine (miscellaneous)Genes InsectApoptosisDystrophyInhibitor of Apoptosis ProteinsAnimals Genetically ModifiedCTG repeat expansion0302 clinical medicineImmunology and Microbiology (miscellaneous)Drosophila ProteinsMyotonic DystrophyMyocyte0303 health sciencesTOR Serine-Threonine KinasesMyotonin-protein kinaseNuclear ProteinsMuscle atrophyUp-RegulationCell biologyMuscular AtrophyDrosophila melanogastermedicine.anatomical_structureFemalemedicine.symptomSignal TransductionResearch Articlelcsh:RB1-214congenital hereditary and neonatal diseases and abnormalitiesProgrammed cell deathNeuroscience (miscellaneous)BiologyMyotonic dystrophyMyotonin-Protein KinaseMuscleblindGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAutophagylcsh:PathologymedicineAnimalsHumans030304 developmental biologylcsh:RAutophagyDystrophySkeletal musclemedicine.diseaseMolecular biologyDisease Models AnimalMuscle atrophyTrinucleotide Repeat Expansion030217 neurology & neurosurgeryDisease Models & Mechanisms
researchProduct

Acid Ceramidase Deficiency

2015

Abstract A deficiency of the lysosomal enzyme ceramidase leads to accumulation of the sphingolipid ceramide in several organs such as skin, liver, brain and other tissues, resulting in a broad spectrum of clinical manifestations. The most common form, called Farber lipogranulomatosis, is characterized by subcutaneous skin nodules and a progressive hoarseness, in many cases also the central nervous system is affected. A lethal hydrops fetalis represents the most severe form. A ceramidase deficiency was also found in a few patients in whom neurological symptoms such as spinal muscular atrophy and myoclonus epilepsy dominated the clinical picture. In the ceramidase gene, which has been mapped …

medicine.medical_specialtyFarber diseasePathologyGenetic enhancementCentral nervous systemProgressive myoclonus epilepsySpinal muscular atrophyBiologyCeramidasemedicine.diseaseSphingolipidEndocrinologymedicine.anatomical_structureHydrops fetalisInternal medicinemedicine
researchProduct

Neurodegenerative changes are prevented by Erythropoietin in the pmn model of motoneuron degeneration

2014

Motoneuron diseases are fatal neurodegenerative disorders characterized by a progressive loss of motoneurons, muscle weakness and premature death. The progressive motor neuronopathy (pmn) mutant mouse has been considered a good model for the autosomal recessive childhood form of spinal muscular atrophy (SMA). Here, we investigated the therapeutic potential of Erythropoietin (Epo) on this mutant mouse. Symptomatic or pre-symptomatic treatment with Epo significantly prolongs lifespan by 84.6% or 87.2% respectively. Epo preserves muscle strength and significantly attenuates behavioural motor deficits of mutant pmn mice. Histological and metabolic changes in the spinal cord evaluated by immunoh…

medicine.medical_specialtyMutantMotor ActivitySpinal Muscular Atrophies of ChildhoodMiceCellular and Molecular NeuroscienceWestern blotInternal medicineReceptors ErythropoietinmedicineAnimalsErythropoietinMotor NeuronsPharmacologymedicine.diagnostic_testbusiness.industryMuscle weaknessSpinal muscular atrophymedicine.diseaseSpinal cordSMA*Mice Mutant StrainsDisease Models Animalmedicine.anatomical_structureEndocrinologySpinal CordErythropoietinImmunohistochemistrymedicine.symptombusinessNeurosciencemedicine.drugNeuropharmacology
researchProduct

Effects of intermittent high frequency electrical stimulation on denervated EDL muscle of rabbit.

1990

This study was performed to determine whether electrical stimulation can retard denervation-induced changes. The denervated extensor digitorum longus of the rabbit, a fast-twitch muscle, was stimulated at a rate mimicking its motoneuron firing pattern. The 100-Hz stimulation given intermittently subjected the muscle to a low mean total daily frequency of 1.6 Hz. Four weeks of stimulation resulted in no effect upon the denervated stimulated muscle. This stimulation protocol, therefore, is unable to substitute for the lost neuronal influence of the nerve. The muscle contralateral to the stimulated side showed physiological changes making it unsuitable to serve as a control.

medicine.medical_specialtyPhysiologyStimulationCellular and Molecular NeuroscienceAtrophyPhysiology (medical)Internal medicinemedicineAnimalsDenervationContraction timeLagomorphabiologyChemistryElectromyographyMusclesAnatomymusculoskeletal systembiology.organism_classificationmedicine.diseaseAmyotrophyElectric StimulationMuscle DenervationMuscular AtrophyEndocrinologyNeurology (clinical)RabbitsMuscle ContractionMusclenerve
researchProduct

G.P.232

2014

Spinal muscular atrophy (SMA) and Pompe disease (PD) are common neuromuscular disorders during childhood causing progressive weakness of proximal muscles with gait disturbances, loss of ambulation and breathing difficulties. Whereas SMA is the result of a neurogenic atrophy caused by mutations in the SMN1 gene, PD is a lysosomal glycogen storage disease (type II) due to mutations of the GAA gene responsible for the enzyme activity of acid alpha-1,4-glucosidase. PD is treatable by enzyme replacement therapy, but in SMA there is no established curable therapy. We report on a child with genetically proven SMA type III and PD caused by mutations in the SMN1 and GAA genes. A 3 years old girl pre…

medicine.medical_specialtySMN1BiologyFasciculation03 medical and health sciences0302 clinical medicine030225 pediatricsInternal medicinemedicineOutpatient clinicGlycogen storage diseaseGenetics (clinical)Muscle biopsymedicine.diagnostic_testEnzyme replacement therapyAnatomySpinal muscular atrophymedicine.diseaseSMA*3. Good healthEndocrinologyNeurologyPediatrics Perinatology and Child HealthNeurology (clinical)medicine.symptom030217 neurology & neurosurgeryNeuromuscular Disorders
researchProduct

Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy

2021

ABSTRACTObjectiveTo assess in adult spinal muscular atrophy (SMA) patients the construct validity and responsiveness of several outcome measures.MethodsPatients older than 15 years and followed-up at least for 6 months, between October 2015 and August 2020, with one motor function scale (Hammersmith Functional Motor Scale Expanded, HFMSE; Revised Upper Limb module, RULM) in five referral centers were included. Bedside functional scales (Egen Klassification, EK2; Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, ALSFRS-R) were also collected when available. Correlations and regression models were performed to evaluate the construct validity. The monthly slopes of change were use…

medicine.medical_specialtybusiness.industryConstruct validityRegression analysisSpinal muscular atrophymedicine.diseaseSMA*Physical medicine and rehabilitationmedicine.anatomical_structureRating scaleFloor effectmedicineUpper limbAmyotrophic lateral sclerosisbusiness
researchProduct